BioMarin Pharmaceutical Financial Statements
NASDAQ: BMRNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
BioMarin Pharmaceutical revenue and earnings
In fiscal 2025, BioMarin Pharmaceutical generated $3.22 billion in revenue, up 12.9% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $348.9 million (-18.3% year over year), for a net margin of 10.8% versus a median of 6.9% in the prior 5 years. Gross margin was 77.7% (down from 79.7%) and operating margin 12.7%.
Diluted earnings per share came in at $1.80, down from $2.21. Over the last 5 fiscal years, BMRN's revenue has grown at a 11.6% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
BioMarin Pharmaceutical income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3.22B | 2.85B | 2.42B | 2.10B | 1.85B | 1.86B | 1.70B | 1.49B | 1.31B | 1.12B |
| Revenue growth (YoY) | +12.87% | +17.97% | +15.42% | +13.53% | -0.76% | +9.18% | +14.27% | +13.52% | +17.62% | +25.50% |
| Cost of Revenue | 717.44M | 580.24M | 532.06M | 503.02M | 470.51M | 524.27M | 359.47M | 315.26M | 241.79M | 209.62M |
| Gross Profit | 2.50B | 2.27B | 1.89B | 1.59B | 1.38B | 1.34B | 1.34B | 1.18B | 1.07B | 907.23M |
| Operating Expenses | 2.09B | 1.79B | 1.70B | 1.43B | 1.46B | 1.38B | 1.45B | 1.30B | 1.09B | 1.71B |
| Research & Development | 921.93M | 747.18M | 746.77M | 649.61M | 628.79M | 628.12M | 715.01M | 696.33M | 610.75M | 661.90M |
| Selling, General & Admin | 1.15B | 1.01B | 892.41M | 823.24M | 759.38M | 737.67M | 680.92M | 604.35M | 554.34M | 476.59M |
| Operating Income | 409.48M | 484.21M | 185.77M | 160.97M | -82.34M | -43.44M | -100.46M | -123.52M | -14.70M | -803.43M |
| Interest Expense | 10.90M | 12.67M | 17.34M | 15.97M | 15.34M | 29.31M | 23.46M | 43.66M | 42.71M | 39.50M |
| Pretax Income | 482.48M | 541.76M | 188.56M | 149.58M | -75.35M | -49.00M | -94.81M | -142.71M | -35.88M | -831.05M |
| Income Tax | 133.58M | 114.90M | 20.92M | 8.02M | -11.27M | -903.03M | -70.96M | -65.49M | 81.17M | -200.84M |
| Net Income | 348.90M | 426.86M | 167.65M | 141.56M | -64.08M | 854.03M | -23.85M | -77.21M | -117.04M | -630.21M |
| Net Income growth (YoY) | -18.26% | +154.62% | +18.43% | — | -107.50% | — | — | — | — | — |
| EPS (Basic) | 1.82 | 2.25 | 0.89 | 0.76 | -0.35 | 4.72 | -0.13 | -0.44 | -0.67 | -3.80 |
| EPS (Diluted) | 1.80 | 2.21 | 0.87 | 0.75 | -0.35 | 4.50 | -0.13 | -0.44 | -0.67 | -3.81 |
| Shares Outstanding (Basic) | 191.79M | 190.03M | 187.83M | 185.27M | 182.85M | 180.80M | 179.04M | 177.06M | 174.43M | 165.99M |
| Shares Outstanding (Diluted) | 197.39M | 196.71M | 191.59M | 188.96M | 182.85M | 191.68M | 179.04M | 177.27M | 174.43M | 166.22M |
| EBITDA | 489.04M | 580.64M | 290.16M | 262.94M | 25.70M | 61.73M | 4.84M | -27.85M | 73.16M | -706.52M |
| Gross Margin | 77.73% | 79.67% | 78.01% | 76.00% | 74.52% | 71.82% | 78.91% | 78.86% | 81.59% | 81.23% |
| Operating Margin | 12.71% | 16.97% | 7.68% | 7.68% | -4.46% | -2.33% | -5.90% | -8.28% | -112.00% | -71.94% |
| Net Margin | 10.83% | 14.96% | 6.93% | 6.75% | -3.47% | 45.90% | -140.00% | -5.18% | -8.91% | -56.43% |
This table shows 10 annual periods of BioMarin Pharmaceutical's income statement, from FY 2025 back to FY 2016, across 19 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow BMRN's reporting calendar. What is a income statement?